Affiliation:
1. Department of Obstetrics and Gynecology Gunma University Graduate School of Medicine Maebashi Japan
2. Asada Ladies Clinic Nagoya Japan
3. Department of Frontier Medicine, Institute of Medical Science St. Marianna University School of Medicine Kawasaki Japan
4. Department of Obstetrics and Gynecology Nagoya University Graduate School of Medicine Nagoya Japan
5. Department of Obstetrics and Gynecology Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan
6. Department of Obstetrics and Gynaecology Juntendo University Faculty of Medicine Tokyo Japan
Abstract
AbstractAimTo present evidence‐based recommendations for anti‐Müllerian hormone (AMH) measurement as an ovarian reserve test.MethodsA systematic literature search for the clinical utility of AMH was conducted in PubMed from its inception to August 2022 to identify studies, including meta‐analyses, reviews, randomized controlled trials, and clinical trials, followed by an additional systematic search using keywords. Based on this evidence, an expert panel developed clinical questions (CQs).ResultsA total of 1895 studies were identified and 95 articles were included to establish expert opinions subdivided into general population, infertility treatment, primary ovarian insufficiency, polycystic ovary syndrome, surgery, and oncofertility. We developed 13 CQs and 1 future research question with levels of evidence and recommendations.ConclusionThe findings of the current systematic review covered the clinical utility of AMH including its screening, diagnosis, evaluation, and prediction. Although some clinical implications of AMH remain debatable, these expert opinions may help promote a better understanding of AMH and establish its clinical significance.
Subject
Obstetrics and Gynecology